Sat Sep 14 08:56:00 UTC 2024: ## Instil Bio Soars on Potential Blockbuster Drug, But Risks Remain

**September 14, 2024** – Small-cap biopharmaceutical company Instil Bio (TIL) has seen its stock price skyrocket by over 500% year-to-date, fueled by optimism surrounding its new drug candidate, IMM2510. This bispecific antibody, which targets PD-L1 and VEGF, shows similarities to ivonescimab, a drug already approved in China and showing promising results in head-to-head trials against the world’s top-selling cancer therapy, Keytruda.

Analyst Jack Allen of Baird has raised his price target on Instil Bio to $180 per share, implying a potential gain of 235% from current levels. While this enthusiasm is understandable, investors should be aware of the significant risks associated with this high-risk, high-reward investment.

IMM2510 is still in early phase 1 trials, and its effectiveness and safety have yet to be fully established. The limited data available so far show mixed results, with only three out of 25 patients experiencing tumor shrinkage in a recent study.

Furthermore, it’s not certain whether a bispecific antibody targeting PD-1 and VEGF will be superior to existing treatments using a combination of PD-1 and anti-VEGF drugs.

Instil Bio also faces significant financial challenges. While it has recently secured a 15-year lease agreement with AstraZeneca for a cell therapy manufacturing site, the company is still burning through cash at a rapid pace. The lack of recurring revenue from commercialized products means further capital raises will likely be necessary in the future.

Investors should carefully consider their risk tolerance before investing in Instil Bio. While the potential rewards are significant, the possibility of failure is equally real. For investors seeking a more stable and less volatile investment, Instil Bio may not be the right choice.

Read More